Table 2.
Control | Obesity | p value | |
---|---|---|---|
n = 19 | n = 18 | ||
Fasting blood glucose (mg/dL) | 87,61 ± 5,55 | 87,59 ± 6,25 | 0,936 |
2 h glucose (mg/dL) | 91,74 ± 13 | 94,23 ± 13,58 | 0,7617 |
Insulin (mcU/mL) | 7,77 ± 4,78 | 19,77 ± 8,02 | < 0,0001** |
Total cholesterol (mg/dL) | 150,15 ± 21,83 | 158,29 ± 24,91 | 0,3758 |
Triglycerides (mg/dL) | 76,48 ± 18,47 | 117,27 ± 31,64 | 0,0001* |
HDL (mg/dL) | 50,34 ± 8,22 | 41,39 ± 9,51 | 0,0077* |
LDL (mg/dL) | 84,55 ± 18,04 | 94,70 ± 20,67 | 0,2547 |
VLDL (mg/dL) | 15,29 ± 3,69 | 23,45 ± 6.33 | 0,0001** |
HOMA-IR (score) | 1,50 ± 1,19 | 4,28 ± 1,72 | < 0,0001** |
TG/HDL ratio | 1,60 ± 0,61 | 3,02 ± 1,24 | < 0,0001** |
Android-gynoid % fat ratio | 0,61 ± 0,17 | 0,99 ± 0,08 | < 0,0001** |
GLP-1 (ng/mL) | 15,98 ± 0,69 | 17,70 ± 0,66 | 0,0725 |
GIP (pg/mL) | 2637 ± 486,89 | 3137 ± 512,44 | 0,6299 |
Values are presented as percentage or mean ± standard deviation (SD). Differences between groups were evaluated using Wilcoxon signed-rank tests
* p < 0.005, ** p < 0.0001
aHDL high-density lipoprotein, VLDL very low-density lipoprotein, LDL low-density lipoprotein, HOMA-IR homeostatic model of assessment for insulin resistance, GLP-1 glucagon-like peptide 1, GIP gastric inhibitory polypeptide